Harmony Bio Faces Significant Setback: Fragile X Syndrome Therapy Misses Primary Endpoint in Pivotal Trial
MBX Biosciences Rockets Skyward: Breakthrough Hypoparathyroidism Drug Unlocks Massive Pre-Market Surge!
A Major Setback for Amgen: Bemarituzumab's Gastric Cancer Ambitions Dim as Final Data Fails to Impress